UnfairGaps
🇩🇪Germany

Kapazitätsverluste durch HTA-Bewertungsengpässe

1 verified sources

Definition

New HTA requirements parallel to approvals create bottlenecks, leading to idle equipment and lost sales opportunities.

Key Findings

  • Financial Impact: 2-5% Kapazitätsverlust = €100.000-€500.000/Jahr pro Linie (bei €10M Umsatz)
  • Frequency: From Jan 2025 for oncology/ATMPs
  • Root Cause: Parallel EU-level assessments without optimized submission processes

Why This Matters

This pain point represents a significant opportunity for B2B solutions targeting Medical Equipment Manufacturing.

Affected Stakeholders

Production Manager, Regulatory Team, Supply Chain

Action Plan

Run AI-powered research on this problem. Each action generates a detailed report with sources.

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Related Business Risks